Navigation Links
Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain
Date:11/28/2008

that the product will receive regulatory approval for chronic pain, or that it will continue to be commercially successful. For further discussion of these and other risks and uncertainties, see Lilly's filings with the United States Securities and Exchange Commission. Lilly undertakes no duty to update forward-looking statements.

    (i)    Chappell, A. et al. Duloxetine 60 to 120 mg versus Placebo in the
           Treatment of Patients with Osteoarthritis Knee Pain. Poster
           presented at the European League Against Rheumatism. 13 June 2008.
    (ii)   Skljarevski, V. et al. Efficacy of Duloxetine in Chronic Low Back
           Pain.  Poster presented at the European Federation of Neurological
           Societies Annual Congress. 25 August 2008.
    (iii)  Skljarevski, V. et al. Duloxetine versus Placebo in the Treatment
           of Chronic Low Back Pain.  Poster presented at the 12th World
           Congress of Pain. 21 August 2008.
    (iv)   APF 2008.
    (v)    NIH 1998.
    (vi)   Fox et al. 2000.
    (vii)  Stewart et al. 2003.
    (viii) White et al. 2005.

    (Logo:http://www.newscom.com/cgi-bin/prnh/20031219/LLYLOGO )


'/>"/>
SOURCE Eli Lilly and Company
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Daiichi Sankyo and Lilly Respond to Speculation on Status of Prasugrel New Drug Application
2. Lilly and Deciphera Pharmaceuticals Announce Licensing and Collaboration Agreement
3. Lilly Announces Initiation of Second Global Phase III Trial of Investigational Alzheimers Disease Compound
4. Insulin Analogues From Novo Nordisk, Eli Lilly and Sanofi-Aventis Will Drive Growth in the Type 1 Diabetes Drug Market
5. Phase II Data on Lillys Antibody Show It Affects Amyloid Beta, a Protein Believed To Be Associated with Alzheimers Disease
6. FDA Extends Review Period for Daiichi Sankyo, Lilly Investigative Antiplatelet Drug, Prasugrel
7. Lilly and TransPharma Medical Announce Licensing and Development Agreement
8. Lilly Submits Cymbalta(R) Supplemental New Drug Application for Chronic Pain to U.S. Food and Drug Administration
9. Daiichi Sankyo/Eli Lillys Effient and Astrazenecas Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction
10. Lilly Launches Its First Phase III Trial for Treatment of Alzheimers Disease
11. Lilly and Transition Therapeutics Announce Licensing and Collaboration Agreement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)... February 26, 2015 ABIVAX, a clinical ... vaccines, today announced that it has dosed in ... IIb/III clinical trial of ABX203 which is taking place in ... The study is designed to assess whether ABX203 can deliver ... (CHB) via controlling viral load for a much longer period ...
(Date:2/26/2015)... 2015   HeartWare International, Inc . (NASDAQ: ... miniaturized circulatory support technologies that are revolutionizing the treatment ... million for the fourth quarter ended December 31, 2014, ... for the same period of 2013.  For the fiscal ... a 34% increase compared to revenue of $207.9 million ...
(Date:2/26/2015)... 26, 2015  Caris Life Sciences® today announced ... Genitourinary Cancers Symposium in Orlando, Fla. ... the Audio Poster Tour. Both studies utilized Caris ... service. These studies showed that panomic testing can ... carcinomas (RCC), providing insights that may drive selection ...
Breaking Medicine Technology:ABIVAX Recruits First Patient in a Pivotal Phase IIb/III Clinical Trial with ABX203, a Novel Immunotherapy Against Chronic Hepatitis B 2ABIVAX Recruits First Patient in a Pivotal Phase IIb/III Clinical Trial with ABX203, a Novel Immunotherapy Against Chronic Hepatitis B 3ABIVAX Recruits First Patient in a Pivotal Phase IIb/III Clinical Trial with ABX203, a Novel Immunotherapy Against Chronic Hepatitis B 4ABIVAX Recruits First Patient in a Pivotal Phase IIb/III Clinical Trial with ABX203, a Novel Immunotherapy Against Chronic Hepatitis B 5HeartWare International Reports $73.2 Million In Fourth Quarter 2014 Revenue; 38% Increase From Fourth Quarter 2013 2HeartWare International Reports $73.2 Million In Fourth Quarter 2014 Revenue; 38% Increase From Fourth Quarter 2013 3HeartWare International Reports $73.2 Million In Fourth Quarter 2014 Revenue; 38% Increase From Fourth Quarter 2013 4HeartWare International Reports $73.2 Million In Fourth Quarter 2014 Revenue; 38% Increase From Fourth Quarter 2013 5HeartWare International Reports $73.2 Million In Fourth Quarter 2014 Revenue; 38% Increase From Fourth Quarter 2013 6HeartWare International Reports $73.2 Million In Fourth Quarter 2014 Revenue; 38% Increase From Fourth Quarter 2013 7HeartWare International Reports $73.2 Million In Fourth Quarter 2014 Revenue; 38% Increase From Fourth Quarter 2013 8HeartWare International Reports $73.2 Million In Fourth Quarter 2014 Revenue; 38% Increase From Fourth Quarter 2013 9HeartWare International Reports $73.2 Million In Fourth Quarter 2014 Revenue; 38% Increase From Fourth Quarter 2013 10HeartWare International Reports $73.2 Million In Fourth Quarter 2014 Revenue; 38% Increase From Fourth Quarter 2013 11HeartWare International Reports $73.2 Million In Fourth Quarter 2014 Revenue; 38% Increase From Fourth Quarter 2013 12Caris Life Sciences' Multiplatform Tumor Profiling Helps to Identify Potential Predictive Biomarkers in Renal Cell Carcinoma 2Caris Life Sciences' Multiplatform Tumor Profiling Helps to Identify Potential Predictive Biomarkers in Renal Cell Carcinoma 3Caris Life Sciences' Multiplatform Tumor Profiling Helps to Identify Potential Predictive Biomarkers in Renal Cell Carcinoma 4Caris Life Sciences' Multiplatform Tumor Profiling Helps to Identify Potential Predictive Biomarkers in Renal Cell Carcinoma 5
... DATA ), a technology and services company focused ... reported its,operating results for the first quarter of 2008., ... revenue decreased,approximately 41% to $2,088,000 and the Company reported ... both a basic and diluted basis. These,results compared with ...
... data support potential of asenapine in the treatment of ... schizophrenia and bipolar I ... ) today announced that an overview of asenapine clinical trials,from ... of the,American Psychiatric Association in Washington, D.C., May 3-8. Data ...
Cached Medicine Technology:DATATRAK International Reports First Quarter Results for 2008 2DATATRAK International Reports First Quarter Results for 2008 3DATATRAK International Reports First Quarter Results for 2008 4DATATRAK International Reports First Quarter Results for 2008 5DATATRAK International Reports First Quarter Results for 2008 6DATATRAK International Reports First Quarter Results for 2008 7Overview of Asenapine Data from Olympia Trial Program Presented at American Psychiatric Association Annual Meeting 2Overview of Asenapine Data from Olympia Trial Program Presented at American Psychiatric Association Annual Meeting 3Overview of Asenapine Data from Olympia Trial Program Presented at American Psychiatric Association Annual Meeting 4Overview of Asenapine Data from Olympia Trial Program Presented at American Psychiatric Association Annual Meeting 5Overview of Asenapine Data from Olympia Trial Program Presented at American Psychiatric Association Annual Meeting 6Overview of Asenapine Data from Olympia Trial Program Presented at American Psychiatric Association Annual Meeting 7
(Date:2/26/2015)... 2015 Deep Market Research Report on ... study on the current state of the global ... the Chinese situation. , Major companies included in ... Hu-Friedy, Medisporex, Towne Brothers, Teleflex Medical, Landanger, YDM, ... Equipment, Shuanglu, Changshu Henry Medical Instrument, and Kangqiao ...
(Date:2/26/2015)... 2015 “ KnowNote ” was featured on ... latest and coolest mobile applications on the iOS, Android, and ... of NewsWatch, conducted the app review and shared with viewers ... rhythm and in tune. , Learning a musical instrument can ... what if people could take something they already know and ...
(Date:2/26/2015)... Claflin Medical Equipment , a Rhode Island based medical ... based medical equipment distributor, have announced a merger effective ... premier organizations that specialize in equipment and the logistics ... By combining forces, they can now cover the entire ... Claflin will gain even greater reach with their government ...
(Date:2/26/2015)... Pittsburgh, PA (PRWEB) February 26, 2015 ... Chairman J. Robert Baum, Ph.D. is stepping down as ... succeeded by Joseph C. Guyaux, senior vice chairman of ... chief executive officer, PNC Mortgage. Additionally, Highmark Health President ... the chairman of the board of directors of Highmark ...
(Date:2/26/2015)... 26, 2015 Growth in the ... by a EuroMonitor International Report that U.S. men’s ... In response to the robust demand for ... launching a barbering program in partnership with internationally ... Factory” salon. The proprietary curriculum features 10 signature ...
Breaking Medicine News(10 mins):Health News:Global Hemostat Industry Data, Size and Growth Report 2015-2020 Now Available at DeepResearchReports.com 2Health News:Global Hemostat Industry Data, Size and Growth Report 2015-2020 Now Available at DeepResearchReports.com 3Health News:A Modern Way to Learn Music was Featured on NewsWatch Television on January 30, 2015 2Health News:Claflin Medical Equipment Announces Merger with Hospital Associates 2Health News:Highmark Health Appoints Joseph C. Guyaux Chairman of the Board of Directors 2Health News:Highmark Health Appoints Joseph C. Guyaux Chairman of the Board of Directors 3Health News:Highmark Health Appoints Joseph C. Guyaux Chairman of the Board of Directors 4Health News:Bellus Academy Partners with Renowned Hairstylist D.J. Muldoon to Launch Signature Barbering Program 2
... ... tidbits people are learning about their ancestors is not just trivia. This information is highly ... understanding their familial and ancestral past. , ... Doylestown, PA (PRWEB) March 13, 2010 -- Noted author Donna Evans Strauss ...
... (Nasdaq: SIAL ) today announced that it has entered into an agreement with Pfizer under which Sigma-Aldrich will sell approximately 100 Pfizer-developed small ... ... , , ... ...
... 19 year olds and to those currently not in employment in a bid to increase awareness of safety at work. , ... , , ... ... ...
... 15, 2010 The Autism Consortium, an innovative research, ... enhancing clinical care for families with autism spectrum disorders ... study of genetic testing methods for autism spectrum disorders ... early online release in their eFirst pages today and ...
... AllegroMedical.com, ... meaning that just under 13 years, it has served more than a million customers nationwide. ... (Vocus) March 14, 2010 ... website launched in 1997. The first company to sell medical supplies online, it has grown ...
... its kind to date using cardiac computed tomography angiography, ... coronary artery disease are at higher risk of developing ... Henry Ford Hospital researchers say. Researchers analyzed the ... computed tomography angiography and found that those with a ...
Cached Medicine News:Health News:Author Proves What Celebrities are Learning in "Who Do You Think You Are?" is More Important Than They Realize 2Health News:Sigma-Aldrich Reaches Agreement to Sell Pfizer's Bioactive Small Molecule Compounds 2Health News:Sigma-Aldrich Reaches Agreement to Sell Pfizer's Bioactive Small Molecule Compounds 3Health News:Sigma-Aldrich Reaches Agreement to Sell Pfizer's Bioactive Small Molecule Compounds 4Health News:Sigma-Aldrich Reaches Agreement to Sell Pfizer's Bioactive Small Molecule Compounds 5Health News:British Safety Council Offers Free Health and Safety Qualifications 2Health News:Autism Consortium study in Pediatrics shows CMA finds more genetic abnormalities than current tests 2Health News:Autism Consortium study in Pediatrics shows CMA finds more genetic abnormalities than current tests 3Health News:Autism Consortium study in Pediatrics shows CMA finds more genetic abnormalities than current tests 4Health News:Online Medical Supplies Superstore Ships 1 Millionth Order 2Health News:Family history is strong predictor of obstructive coronary artery disease using CCTA 2
Colloidal Gold Sol, 20 nm - 50 OD, 1 ml, Gold Sol Nanoparticles - not boiled, not centrifuged...
... PalmScan P2000 Pachymeter [i.e., PalmScan P2000] ... operated biometer, which incorporates A-mode pulsed-echo ... to accurately measure the corneal thickness ... eyes. PalmScan P2000 includes two software ...
... PalmScan A2000 A-Scan [i.e., PalmScan A2000] device ... which incorporates A-mode pulsed-echo ultrasound,technology, and thus ... axial length (AL), anterior,chamber depth (ACD), and ... PalmScan A2000,device is also intended for calculating ...
... low TLR (<1%) and stroke rate - ... long-term durability., , , High Radial Strength: ... artery, increasing lumen diameter with chronic outward ... stent shortening, low profile design, Cordis TRUMARK™ ...
Medicine Products: